Boston Scientific(US:BSX) Businesswire·2026-03-06 21:27Core Viewpoint - A class action lawsuit has been filed against Boston Scientific Corporation (BSX) for securities fraud, following disappointing financial results and guidance that fell below investor expectations [1] Group 1: Lawsuit Details - The class action lawsuit is on behalf of investors who purchased Boston Scientific securities between July 23, 2025, and February 3, 2026, with a deadline of May 4, 2026, to file a lead plaintiff motion [1] - The lawsuit alleges that Boston Scientific made materially false and misleading statements regarding its business operations and growth prospects, particularly in the U.S. Electrophysiology (EP) segment [1] Group 2: Financial Performance - On February 4, 2026, Boston Scientific reported its fourth quarter and full year 2025 results, highlighting a disappointing performance in U.S. Electrophysiology sales and issued fiscal 2026 guidance that was below expectations [1] - The company's stock price fell by $16.12, or 17.6%, closing at $75.50 per share on the day of the announcement, indicating significant investor loss [1] Group 3: Allegations Against the Company - The lawsuit claims that Boston Scientific failed to disclose that the growth rate of its U.S. EP segment was unsustainable and that new competition was negatively impacting its market share [1] - It is alleged that the company's previous statements of confidence regarding the growth trajectory of the U.S. EP division were materially misleading and lacked a reasonable basis [1]